Fiche publication
Date publication
août 2017
Journal
Oncotarget
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BRONNER Christian
,
Dr HAMICHE Ali
,
Pr MELY Yves
,
Dr MOUSLI Marc
Tous les auteurs :
Ashraf W, Ibrahim A, Alhosin M, Zaayter L, Ouararhni K, Papin C, Ahmad T, Hamiche A, Mély Y, Bronner C, Mousli M
Lien Pubmed
Résumé
Cancer is one of the deadliest diseases in the world causing record number of mortalities in both developed and undeveloped countries. Despite a lot of advances and breakthroughs in the field of oncology still, it is very hard to diagnose and treat the cancers at early stages. Here in this review we analyze the potential of Ubiquitin-like containing PHD and Ring Finger domain 1 (UHRF1) as a universal biomarker for cancers. UHRF1 is an important epigenetic regulator maintaining DNA methylation and histone code in the cell. It is highly expressed in a variety of cancers and is a well-known oncogene that can disrupt the epigenetic code and override the senescence machinery. Many studies have validated UHRF1 as a powerful diagnostic and prognostic tool to differentially diagnose cancer, predict the therapeutic response and assess the risk of tumor progression and recurrence. Highly sensitive, non-invasive and cost effective approaches are therefore needed to assess the level of UHRF1 in patients, which can be deployed in diagnostic laboratories to detect cancer and monitor disease progression.
Mots clés
DNA methylation, UHRF1, biomarkers, cancer, epigenetics
Référence
Oncotarget. 2017 Aug;8(31):51946-51962
